Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06WPM
|
|||
| Former ID |
DIB004329
|
|||
| Drug Name |
Coprexa
|
|||
| Synonyms |
Tetrathiomolybdate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurological disorder [ICD-11: 6B60] | Phase 3 | [1] | |
| Company |
Pipex Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
H2MoS4-2
|
|||
| Canonical SMILES |
[SH-].[SH-].S=[Mo]=S
|
|||
| InChI |
1S/Mo.2H2S.2S/h;2*1H2;;/p-2
|
|||
| InChIKey |
VVRHUOPINLMZBL-UHFFFAOYSA-L
|
|||
| CAS Number |
CAS 16330-92-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:30703
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Inhibitor | [1] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.